Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension

The American Journal of Cardiology

Volumn 53, Issue 1, 1984, Pages 105-108

  Dunn, Francis G ^a,b   Oigman, Wille ^a,b   Ventura, Hector O ^a,b   Messerli, Franz H ^a,b   Kobrin, Isaac ^a,b   Frohlich, Edward D ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; ENALAPRIL; HYDROCHLOROTHIAZIDE;

BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG DOSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG THERAPY; ESSENTIAL HYPERTENSION; HEART; HEART INDEX; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HUMAN EXPERIMENT; KIDNEY; KIDNEY BLOOD FLOW; METHODOLOGY; ORAL DRUG ADMINISTRATION; THERAPY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DIPEPTIDES; ECHOCARDIOGRAPHY; ENALAPRIL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIUM; RENAL CIRCULATION;

EID: 0021364719     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(84)90692-1     Document Type: Article

References (28)

1. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421) an orally active converting enzyme inhibitor
2. Relationship between angiotensin 1 blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats
3. Comparative effects of captopril and MK-421 on sympathetic function in spontaneously hypertensive rats
4. Effect of a new angiotensin converting enzyme inhibitor MK-421 and its lysine analogue on the components of the renin system in healthy subjects
5. A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension
6. Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension
7. A simple radioassay for angiotensin-converting enzyme
8. Systemic and regional hemodynamics in low, normal, and high cardiac output borderline hypertension
9. Hemodynamic and metabolic alterations induced by acute and chronic timolol therapy in hypertensive man
10. Pathophysiologic assessment of hypertensive heart disease with echocardiography
11. Left ventricular wall thickness measured by ultrasound
12. Analysis of left ventricular wall motion by reflected ultrasound. Application to assessment of myocardial function
13. Problems in echocardiographic volume determinations. Echocardiographic-angiographic correlations in the presence or absence of asynergy
14. Correlation of left ventricular mass determined by echocardiography with vectorcardiographic and electrocardiographic voltage measurements
15. Serial measurements of left ventricular dimensions by echocardiography
16. Physiological and pharmacological characterization of the area postrema pressor pathways in the normal dog
17. Arterial hypertension elicited by subpressor amounts of angiotensin
18. Mechanisms of cardioaccelerator action of angiotensin
19. Cardioacceleration action of angiotensin
20. Nature of the inotropic action of angiotensin on ventricular myocardium
21. Increased renal plasma flow during longterm treatment of essential hypertension with MK-421 (abstr)
22. Autoregulation of the total systemic circulation and its relation to control of cardiac output and arterial pressure
23. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat
24. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle
25. Cardiac hypertrophy and antihypertensive therapy
26. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa
27. R-wave voltage changes in relation to arterial pressure in hypertensive patients